Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Macleod, Tom ^a   Doble, Rosella ^a   McGonagle, Dennis ^b,c   Wasson, Christopher W ^a   Alase, Adewonuola ^b   Stacey, Martin ^a   Wittmann, Miriam ^b,c,d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; IL36RN PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; LEUKOCYTE ELASTASE;

CELL CULTURE; ENZYMOLOGY; FIBROBLAST; HUMAN; KERATINOCYTE; METABOLISM; PROTEIN DEGRADATION; SKIN;

ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; FIBROBLASTS; HUMANS; INTERLEUKINS; KERATINOCYTES; LEUKOCYTE ELASTASE; PROTEOLYSIS; SKIN;

EID: 84964277318     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24880     Document Type: Article

References (27)

1. Nestle, F. O., Kaplan, D. H. & Barker, J. Psoriasis. N Engl J Med. 361, 496-509 (2009).
2. Azfar, R. S. & Gelfand, J. M. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 20, 416-422 (2008).
3. Chan, J. R. et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 203, 2577-2587 (2006).
4. Ma, H. L. et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 118, 597-607 (2008).
5. D'Erme, A. M. et al. IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol. 135, 1025-1032 (2015).
6. Towne, J. E., Garka, K. E., Renshaw, B. R., Virca, G. D. & Sims, J. E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 279, 13677-13688 (2004).
7. Towne, J. E. et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem. 286, 42594-42602 (2011).
8. Blumberg, H. et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 204, 2603-2614 (2007).
9. Marrakchi, S. et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 365, 620-628 (2011).
10. Gunther, S. & Sundberg, E. J. Molecular Determinants of Agonist and Antagonist Signaling through the IL-36 Receptor. J Immunol. 193, 921-930 (2014).
11. Farooq, M. et al. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum Mutat. 34, 176-183 (2013).
12. Henry, C. M. et al. Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines. Cell Rep. 14, 708-722 (2016).
13. Vigne, S. et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 118, 5813-5823 (2011).
14. Foster, A. M. et al. IL-36 Promotes Myeloid Cell Infiltration, Activation, and Inflammatory Activity in Skin. J Immunol. 192, 6053-6061 (2014).
15. Carrier, Y. et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 131, 2428-2437 (2011).
16. Mutamba, S., Allison, A., Mahida, Y., Barrow, P. & Foster, N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur J Immunol. 42, 607-617 (2012).
17. Friedrich, M., Tillack, C., Wollenberg, A., Schauber, J. & Brand, S. IL-36gamma sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. Inflamm Bowel Dis. 20, 1891-1901 (2014).
18. Parsanejad, R., Fields, W. R., Steichen, T. J., Bombick, B. R. & Doolittle, D. J. Distinct regulatory profiles of interleukins and chemokines in response to cigarette smoke condensate in normal human bronchial epithelial (NHBE) cells. J Interferon Cytokine Res. 28, 703-712 (2008).
19. Bochkov, Y. A. et al. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol. 3, 69-80 (2010).
20. Vos, J. B. et al. Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiol Genomics. 21, 324-336 (2005).
21. Ramadas, R. A., Ewart, S. L., Iwakura, Y., Medoff, B. D. & LeVine, A. M. IL-36alpha exerts pro-inflammatory effects in the lungs of mice. Plos One. 7, e45784 (2012).
22. Gresnigt, M. S. et al. The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol. 43, 416-426 (2013).
23. Afonina, I. S. et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell. 44, 265-278 (2011).
24. Black, R. A. et al. Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor. J Biol Chem. 263, 9437-9442 (1988).
25. Hazuda, D. J., Strickler, J., Kueppers, F., Simon, P. L. & Young, P. R. Processing of precursor interleukin 1 beta and inflammatory disease. J Biol Chem. 265, 6318-6322 (1990).
26. Joosten, L. A. et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum. 60, 3651-3662 (2009).
27. Lefrancais, E. et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA 109, 1673-1678 (2012).